Michael Hobbs
Psychiatric/Mental Health · Memphis, TNNPI 1174032213
Payments from drug & device makers
Across 859 payments — averaging $26.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Idorsia Pharmaceuticals US Inc$8K
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Johnson & Johnson$1K
- plus $7K from 21 others
What the payments were for
- Speaking & faculty fees$6,40828%
- Travel & lodging$1,1525%
- Food & beverage$15,18566%
- Education$1711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Idorsia Pharmaceuticals US Inc | 20 | $7,892 |
| AbbVie | 171 | $2,795 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 87 | $1,750 |
| Otsuka America Pharmaceutical, Inc. | 105 | $1,464 |
| Alkermes, Inc. | 66 | $1,327 |
| Johnson & Johnson | 56 | $1,078 |
| Supernus Pharmaceuticals, Inc. | 37 | $1,061 |
| Neurocrine Biosciences, Inc. | 49 | $914 |
| Lundbeck LLC | 40 | $707 |
| Vanda Pharmaceuticals Inc. | 40 | $643 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $610 |
| Axsome Therapeutics, Inc. | 29 | $537 |
| Tris Pharma Inc | 28 | $469 |
| Teva Pharmaceuticals USA, Inc. | 14 | $323 |
| Ironshore Pharmaceuticals Inc. | 16 | $261 |
| Merck | 15 | $251 |
| Sunovion Pharmaceuticals Inc. | 11 | $213 |
| Bausch Health US, LLC | 7 | $130 |
| Collegium Pharmaceutical, Inc. | 7 | $109 |
| Corium, LLC | 9 | $100 |
| Indivior Inc. | 5 | $80 |
| Acadia Pharmaceuticals Inc | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| Adlon Therapeutics L.p. | 2 | $42 |
| Noven Therapeutics, LLC | 2 | $24 |
| Neuronetics, Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,915 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 93 | $155,530 |
| IngrezzaValbenazine Tosylate | 13 | $105,528 |
| Invega SustennaPaliperidone Palmitate | 28 | $90,860 |
| VraylarCariprazine Hcl | 54 | $76,941 |
| RexultiBrexpiprazole | 31 | $45,384 |
| Lurasidone Hcl | 36 | $18,610 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $17,737 |
| TrintellixVortioxetine Hydrobromide | 25 | $16,919 |
| BelsomraSuvorexant | 39 | $16,828 |
| QelbreeViloxazine Hcl | 14 | $15,798 |
| CymbaltaDuloxetine Hcl | 18 | $11,683 |
| Paliperidone ErPaliperidone | 36 | $7,827 |
| QuviviqDaridorexant Hcl | 15 | $7,228 |
| Atomoxetine Hcl | 35 | $5,653 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 46 | $4,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,750 | $155,53093 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $914 | $105,52813 claims |
| Johnson & JohnsonInvega Sustenna | $1,078 | $90,86028 claims |
| AbbVieVraylar | $2,795 | $76,94154 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,464 | $45,38431 claims |
| Axsome Therapeutics, Inc.Auvelity | $537 | $17,73718 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $610 | $16,91925 claims |
| MerckBelsomra | $251 | $16,82839 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $1,061 | $15,79814 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $7,892 | $7,22815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Memphis
- Mary AllenMemphis$422K
- Sarah VogelfangerMemphis$94K
- Angela HammondMemphis$16K
- Kristen LockeMemphis$9K
- Latasha GarrettMemphis$8K
- Lisa WilliamsMemphis$8K
- Kristin FitchpatricMemphis$8K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.